[{"address1": "245 Main Street", "address2": "Second Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 500 8080", "website": "https://immuneering.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Benjamin J. Zeskind M.B.A., Ph.D.", "age": 41, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": 898416, "exercisedValue": 0, "unexercisedValue": 374440}, {"maxAge": 1, "name": "Mr. Robert J. Carpenter M.B.A., M.S.", "age": 77, "title": "Co-Founder & Chair Emeritus", "yearBorn": 1946, "fiscalYear": 2022, "totalPay": 83174, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brett M. Hall Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 867917, "exercisedValue": 0, "unexercisedValue": 453376}, {"maxAge": 1, "name": "Ms. Mallory  Morales CPA", "age": 39, "title": "Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer", "yearBorn": 1984, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Paula  George CPA", "title": "Director of Accounting & Operations and Assistant Corporate Controller", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael D. Bookman J.D.", "age": 35, "title": "Chief Legal Officer & Secretary", "yearBorn": 1988, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leah R. Neufeld", "age": 51, "title": "Chief People Officer", "yearBorn": 1972, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  King Ph.D.", "title": "Head of Discovery & VP", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Praveen  Nair Ph.D.", "title": "Head of Translational Pharmacology & VP", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Harold E. Brakewood", "age": 58, "title": "Chief Business Officer", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.68, "open": 6.78, "dayLow": 6.52, "dayHigh": 6.78, "regularMarketPreviousClose": 6.68, "regularMarketOpen": 6.78, "regularMarketDayLow": 6.52, "regularMarketDayHigh": 6.78, "beta": -0.747, "forwardPE": -3.2964823, "volume": 44364, "regularMarketVolume": 44364, "averageVolume": 64881, "averageVolume10days": 96270, "averageDailyVolume10Day": 96270, "bid": 6.53, "ask": 6.69, "bidSize": 1100, "askSize": 800, "marketCap": 192098448, "fiftyTwoWeekLow": 4.56, "fiftyTwoWeekHigh": 14.29, "fiftyDayAverage": 6.3681, "twoHundredDayAverage": 7.722425, "currency": "USD", "enterpriseValue": 110895536, "floatShares": 14395071, "sharesOutstanding": 29283300, "sharesShort": 2702910, "sharesShortPriorMonth": 2635284, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0923, "heldPercentInsiders": 0.27596, "heldPercentInstitutions": 0.55239, "shortRatio": 54.36, "shortPercentOfFloat": 0.1725, "impliedSharesOutstanding": 29283300, "bookValue": 3.094, "priceToBook": 2.1202326, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -53471624, "trailingEps": -1.88, "forwardEps": -1.99, "enterpriseToEbitda": -1.91, "52WeekChange": -0.18, "SandP52WeekChange": 0.3288405, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "IMRX", "underlyingSymbol": "IMRX", "shortName": "Immuneering Corporation", "longName": "Immuneering Corporation", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e5829551-96d1-35fc-9c6d-d258079bf8f6", "messageBoardId": "finmb_308350677", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.56, "targetHighPrice": 25.0, "targetLowPrice": 10.0, "targetMeanPrice": 18.75, "targetMedianPrice": 20.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 85665688, "totalCashPerShare": 2.925, "ebitda": -58060804, "totalDebt": 4462959, "quickRatio": 10.919, "currentRatio": 11.355, "debtToEquity": 4.927, "returnOnAssets": -0.32459, "returnOnEquity": -0.53358, "freeCashflow": -31097564, "operatingCashflow": -48968632, "financialCurrency": "USD", "trailingPegRatio": null}]